NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Cell

Volumn 172, Issue 5, 2018, Pages 1022-1037.e14

  Böttcher, Jan P ^a   Bonavita, Eduardo ^b   Chakravarty, Probir ^a   Blees, Hanna ^a   Cabeza Cabrerizo, Mar ^a   Sammicheli, Stefano ^a   Rogers, Neil C ^a   Sahai, Erik ^a   Zelenay, Santiago ^b   Reis e Sousa, Caetano ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cancer immunotherapy; dendritic cells; immune evasion; tumor immune control; tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; PROSTAGLANDIN E2; RANTES; B RAF KINASE; BRAF PROTEIN, HUMAN; CCL5 PROTEIN, HUMAN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA CHEMOKINE; XCL1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INFILTRATION; CANCER SURVIVAL; CELL FUNCTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CONVENTIONAL TYPE 1 DENDRITIC CELL; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; GENETIC ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TARGET CELL; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHEMOKINE CCL5; CHEMOKINES, C; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DENDRITIC CELLS; DINOPROSTONE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; MELANOMA; MICE; MUTATION; NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 85041637908     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2018.01.004     Document Type: Article

References (54)

1. Alexandre, Y.O., Ghilas, S., Sanchez, C., Le Bon, A., Crozat, K., Dalod, M., XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses. J. Exp. Med. 213 (2016), 75–92.
2. Bachem, A., Güttler, S., Hartung, E., Ebstein, F., Schaefer, M., Tannert, A., Salama, A., Movassaghi, K., Opitz, C., Mages, H.W., et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J. Exp. Med. 207 (2010), 1273–1281.
3. Brewitz, A., Eickhoff, S., Dähling, S., Quast, T., Bedoui, S., Kroczek, R.A., Kurts, C., Garbi, N., Barchet, W., Iannacone, M., et al. CD8+ T cells orchestrate pDC-XCR1+ dendritic cell spatial and functional cooperativity to optimize priming. Immunity 46 (2017), 205–219.
4. Broz, M.L., Binnewies, M., Boldajipour, B., Nelson, A.E., Pollack, J.L., Erle, D.J., Barczak, A., Rosenblum, M.D., Daud, A., Barber, D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26 (2014), 638–652.
5. Chen, J.H., Perry, C.J., Tsui, Y.-C., Staron, M.M., Parish, I.A., Dominguez, C.X., Rosenberg, D.W., Kaech, S.M., Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat. Med. 21 (2015), 327–334.
6. Dannenberg, A.J., Subbaramaiah, K., Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4 (2003), 431–436.
7. Delconte, R.B., Kolesnik, T.B., Dagley, L.F., Rautela, J., Shi, W., Putz, E.M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17 (2016), 816–824.
8. Diefenbach, A., Jensen, E.R., Jamieson, A.M., Raulet, D.H., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001), 165–171.
9. Dorner, B.G., Dorner, M.B., Zhou, X., Opitz, C., Mora, A., Güttler, S., Hutloff, A., Mages, H.W., Ranke, K., Schaefer, M., et al. Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells. Immunity 31 (2009), 823–833.
10. Engblom, C., Pfirschke, C., Pittet, M.J., The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16 (2016), 447–462.
11. Fox, J.C., Nakayama, T., Tyler, R.C., Sander, T.L., Yoshie, O., Volkman, B.F., Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily. Cytokine 71 (2015), 302–311.
12. Gajewski, T.F., Schreiber, H., Fu, Y.-X., Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
13. Gasser, S., Orsulic, S., Brown, E.J., Raulet, D.H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005), 1186–1190.
14. Ginhoux, F., Liu, K., Helft, J., Bogunovic, M., Greter, M., Hashimoto, D., Price, J., Yin, N., Bromberg, J., Lira, S.A., et al. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206 (2009), 3115–3130.
15. Grajales-Reyes, G.E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., Kc, W., Kretzer, N.M., Briseño, C.G., Durai, V., Bagadia, P., et al. Batf3 maintains autoactivation of Irf8 for commitment of a CD8α(+) conventional DC clonogenic progenitor. Nat. Immunol. 16 (2015), 708–717.
16. Guillerey, C., Huntington, N.D., Smyth, M.J., Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17 (2016), 1025–1036.
17. Guilliams, M., Ginhoux, F., Jakubzick, C., Naik, S.H., Onai, N., Schraml, B.U., Segura, E., Tussiwand, R., Yona, S., Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat. Rev. Immunol. 14 (2014), 571–578.
18. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
19. Hangai, S., Ao, T., Kimura, Y., Matsuki, K., Kawamura, T., Negishi, H., Nishio, J., Kodama, T., Taniguchi, T., Yanai, H., PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc. Natl. Acad. Sci. USA 113 (2016), 3844–3849.
20. Hayday, A.C., Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31 (2009), 184–196.
21. Heidkamp, G.F., Sander, J., Lehmann, C.H.K., Heger, L., Eissing, N., Baranska, A., Lühr, J.J., Hoffmann, A., Reimer, K.C., Lux, A., et al. Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Sci. Immunol. 1 (2016), 1–18.
22. Heng, T.S.P., Painter, M.W., Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9 (2008), 1091–1094.
23. Hildner, K., Edelson, B.T., Purtha, W.E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B.U., Unanue, E.R., Diamond, M.S., et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322 (2008), 1097–1100.
24. Kalinski, P., Regulation of immune responses by prostaglandin E2. J. Immunol. 188 (2012), 21–28.
25. Lavin, Y., Kobayashi, S., Leader, A., Amir, E.D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C.D., Levine, J.H., et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169 (2017), 750–765.
26. Liu, K., Victora, G.D., Schwickert, T.A., Guermonprez, P., Meredith, M.M., Yao, K., Chu, F.F., Randolph, G.J., Rudensky, A.Y., Nussenzweig, M., In vivo analysis of dendritic cell development and homeostasis. Science 324 (2009), 392–397.
27. Mayer, C.T., Ghorbani, P., Nandan, A., Dudek, M., Arnold-Schrauf, C., Hesse, C., Berod, L., Stüve, P., Puttur, F., Merad, M., Sparwasser, T., Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124 (2014), 3081–3091.
28. McColl, S.R., Chemokines and dendritic cells: a crucial alliance. Immunol. Cell Biol. 80 (2002), 489–496.
29. Merad, M., Sathe, P., Helft, J., Miller, J., Mortha, A., The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31 (2013), 563–604.
30. Mittal, D., Vijayan, D., Putz, E.M., Aguilera, A.R., Markey, K.A., Straube, J., Kazakoff, S., Nutt, S.L., Takeda, K., Hill, G.R., et al. Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis. Cancer Immunol. Res. 5 (2017), 1098–1108.
31. Novershtern, N., Subramanian, A., Lawton, L.N., Mak, R.H., Haining, W.N., McConkey, M.E., Habib, N., Yosef, N., Chang, C.Y., Shay, T., et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144 (2011), 296–309.
32. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
33. Ohta, T., Sugiyama, M., Hemmi, H., Yamazaki, C., Okura, S., Sasaki, I., Fukuda, Y., Orimo, T., Ishii, K.J., Hoshino, K., et al. Crucial roles of XCR1-expressing dendritic cells and the XCR1- XCL1 chemokine axis in intestinal immune homeostasis. Sci. Rep., 6, 2016, 23505.
34. Palucka, A.K., Coussens, L.M., The basis of oncoimmunology. Cell 164 (2016), 1233–1247.
35. Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res. 72 (2012), 1407–1415.
36. Poulin, L.F., Reyal, Y., Uronen-Hansson, H., Schraml, B.U., Sancho, D., Murphy, K.M., Håkansson, U.K., Moita, L.F., Agace, W.W., Bonnet, D., Reis e Sousa, C., DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 119 (2012), 6052–6062.
37. Raulet, D.H., Guerra, N., Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 9 (2009), 568–580.
38. Robbins, S.H., Walzer, T., Dembélé D., Thibault, C., Defays, A., Bessou, G., Xu, H., Vivier, E., Sellars, M., Pierre, P., et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol., 9, 2008, R17.
39. Roberts, E.W., Broz, M.L., Binnewies, M., Headley, M.B., Nelson, A.E., Wolf, D.M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M.F., Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30 (2016), 324–336.
40. Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C.M.T., Pryer, N., Daniel, D., Hwang, E.S., Rugo, H.S., Coussens, L.M., Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26 (2014), 623–637.
41. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
42. Sánchez-Paulete, A.R., Cueto, F.J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M.E., Jure-Kunkel, M., Azpilikueta, A., Aznar, M.A., Quetglas, J.I., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6 (2016), 71–79.
43. Sancho, D., Mourão-Sá D., Joffre, O.P., Schulz, O., Rogers, N.C., Pennington, D.J., Carlyle, J.R., Reis e Sousa, C., Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J. Clin. Invest. 118 (2008), 2098–2110.
44. Schlitzer, A., Sivakamasundari, V., Chen, J., Sumatoh, H.R.B., Schreuder, J., Lum, J., Malleret, B., Zhang, S., Larbi, A., Zolezzi, F., et al. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at the common DC progenitor stage in the bone marrow. Nat. Immunol. 16 (2015), 718–728.
45. Serafini, N., Vosshenrich, C.A.J., Di Santo, J.P., Transcriptional regulation of innate lymphoid cell fate. Nat. Rev. Immunol. 15 (2015), 415–428.
46. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
47. Spranger, S., Dai, D., Horton, B., Gajewski, T.F., Tumor-residing Batf3 dendritic cells are required for effector T Cell trafficking and adoptive T cell therapy. Cancer Cell 31 (2017), 711–723.
48. Su, Y., Jackson, E.K., Gorelik, E., Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol. Immunother. 60 (2011), 111–122.
49. Szász, A.M., Lánczky, A., Nagy, Á., Förster, S., Hark, K., Green, J.E., Boussioutas, A., Busuttil, R., Szabó A., Győrffy, B., Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7 (2016), 49322–49333.
50. Velasco-Velázquez, M., Xolalpa, W., Pestell, R.G., The potential to target CCL5/CCR5 in breast cancer. Expert Opin. Ther. Targets 18 (2014), 1265–1275.
51. Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29 (2011), 235–271.
52. Villani, A.-C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J., Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science, 356, 2017, eaah4573.
53. Wendel, M., Galani, I.E., Suri-Payer, E., Cerwenka, A., Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 68 (2008), 8437–8445.
54. Zelenay, S., van der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.